ASH 2021

Conference Coverage

Addressing Barriers to the Use of Gene Therapies and CAR-T Therapies

By

Tori Rodriguez, MA, LPC, AHC

Researchers sought to determine factors limiting access to gene and CAR-T therapies for patients with hematologic disorders.

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL

By

Lauren Dembeck, PhD

Patients were randomly assigned (1:1) to receive either 6 cycles of FCR every 28 days or IR for up to 6 years.

Vienna Prediction Model Identifies Patients With Unprovoked Venous Thromboembolism Who Are at Low Risk of Recurrence

By

Lauren Dembeck, PhD

Researchers sought to create a prediction model to identify patients with unprovoked venous thromboembolism who are at low risk of recurrence.

COVID-19 Vaccination Safe, Effective for Transfusion-Dependent Patients With Beta-Thalassemia

By

Jonathan Goodman, MPhil

Researchers sought to determine whether the COVID-19 mRNA vaccines were safe and effective in patients with transfusion-dependent beta-thalassemia.

Educational Burdens for Children With Sickle Cell Disease in the US Vs Other Nations

By

Vicki Moore, PhD

Researchers sought to determine the educational burdens of children with SCD in the US compared with other nations.

Outcomes in Nontransfusion-Dependent β-Thalassemia With Luspatercept or Placebo

By

Vicki Moore, PhD

Researchers sought to determine whether luspatercept would improve outcomes in patients with nontransfusion-dependent β-thalassemia.

Pegcetacoplan Improves Outcomes Compared With Standard of Care in Patients With Paroxysmal Nocturnal Hemoglobinuria

By

Jonathan Goodman, MPhil

Researchers sought to determine whether pegcetacoplan would be better than standard of care for treating patients with PNH.

Adding Elotuzumab to Myeloma Treatment Regimens Does Not Improve Outcomes

By

Jonathan Goodman, MPhil

Predictors of worse progression-free survival included ISS stage II, ISS stage III, and adverse cytogenetics.

Fitusiran Prophylaxis Improves Annualized Bleeding Rate in Hemophilia A and B

By

Jonathan Goodman, MPhil

Researchers sought to determine whether fitusiran prophylaxis would reduce the rate of bleeding events among patients with hemophilia A or B with inhibitors.

Clonal Hematopoiesis of Indeterminate Potential Associated With Reduced Risk of Alzheimer’s Disease

By

Lauren Dembeck, PhD

Researchers sought to determine whether there was an association between the presence of clonal hematopoiesis of indeterminate potential and protection from Alzheimer’s disease.

Guadecitabine Is Not Superior to Treatment Choice in Patients With Pretreated Acute Myeloid Leukemia

By

Vicki Moore, PhD

Researchers sought to determine whether guadecitabine would have an overall survival benefit for patients with relapsed/refractory acute myeloid leukemia.

Treatment With Azacitidine, Lenalidomide and Donor Lymphocyte Infusion in Myeloid Malignancies After Relapse Following Allo-SCT

By

Lauren Dembeck, PhD

Patients received up to 8 cycles of AZA and up to 3 cycle of DLI with increasing T cell dosages.

Sutimlimab Appears Safe and Efficacious in Patients With Cold Agglutinin Disease

By

Lauren Dembeck, PhD

Researchers sought to determine whether sutimlimab would be safe and effective in treating patients with cold agglutinin disease.

Mesenchymal Stromal Cells Plus Second-Line Therapy Appears Efficacious in Steroid-Resistant Acute Graft-vs-Host Disease

By

Lauren Dembeck, PhD

The study included 203 patients with steroid-resistant acute GVHD who were treated at 10 centers in China between September 2014 and March 2019.

Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.

Low-Dose Inotuzumab Ozogamicin May Be Safe and Effective in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

By

Lauren Dembeck, PhD

Researchers sought to determine whether a low dose of inotuzumab ozogamicin would be safe and effective in patients with relapsed/refractory ALL.

Conditioning Regimens Prior to Autologous Transplantation for Multiple Myeloma

By

Vicki Moore, PhD

A bendamustine-based regimen performed similarly to high-dose melphalan in conditioning prior to autologous stem cell transplantation for multiple myeloma.

Impairments in Some Cognitive Domains in Patients With Sickle Cell Disease

By

Vicki Moore, PhD

Researchers compared cognitive function in patients with SCD with that of healthy control individuals based on factors like stroke history and transfusion history.

Racial/Ethnic and Socioeconomic Disparities in Outcomes Among Children With Acute Lymphoblastic Leukemia

By

Lauren Dembeck, PhD

Researchers sought to determine whether there are disparities by race/ethnicity and socioeconomic status in survival outcomes of children with ALL.

COVID-19 Vaccination Does Not Increase Deep Vein Thrombosis Risk

By

Jonathan Goodman, MPhil

Researchers sought to determine whether vaccination against COVID-19 would increase the risk of developing deep vein thrombosis.